Spots Global Cancer Trial Database for oblimersen sodium
Every month we try and update this database with for oblimersen sodium cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | NCT00736450 | Contiguous Stag... Noncontiguous S... Stage I Adult D... Stage III Adult... Stage IV Adult ... | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... vincristine sul... prednisone biopsy microarray anal... immunohistochem... gene expression... cytogenetic ana... | 19 Years - | University of Nebraska | |
| Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | NCT00070083 | Lymphoma | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 19 Years - | National Cancer Institute (NCI) | |
| Bcl-2 Antisense Oligodeoxynucleotide G3139 and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer | NCT00005032 | Lung Cancer | oblimersen sodi... paclitaxel | 18 Years - | University of Chicago | |
| Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | NCT00004870 | Colorectal Canc... | oblimersen sodi... irinotecan hydr... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia | NCT00004862 | Leukemia | filgrastim oblimersen sodi... cytarabine fludarabine pho... | 16 Years - | National Cancer Institute (NCI) | |
| Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia | NCT00039117 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Secondary Acute... Untreated Adult... | oblimersen sodi... cytarabine daunorubicin hy... laboratory biom... pharmacological... | 60 Years - | National Cancer Institute (NCI) | |
| Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00024440 | Leukemia | filgrastim oblimersen sodi... cyclophosphamid... fludarabine pho... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00049192 | Chronic Myeloge... Chronic Phase C... Relapsing Chron... | oblimersen sodi... imatinib mesyla... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors | NCT00039481 | Cardiac Toxicit... Unspecified Chi... | oblimersen sodi... dexrazoxane hyd... doxorubicin hyd... cyclophosphamid... filgrastim laboratory biom... pharmacological... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Oblimersen in Treating Patients With Merkel Cell Carcinoma | NCT00079131 | Recurrent Neuro... Stage I Neuroen... Stage II Neuroe... Stage III Neuro... Stage IV Neuroe... | oblimersen sodi... pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Olimersen and Irinotecan in Treating Patients With Metastatic or Recurrent Colorectal Cancer | NCT00004870 | Colorectal Canc... | oblimersen sodi... irinotecan hydr... | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | NCT00064259 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage III Esoph... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri... | oblimersen sodi... cisplatin fluorouracil | 19 Years - | National Cancer Institute (NCI) | |
| Oblimersen Sodium & Combination Chemotherapy in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma | NCT00736450 | Contiguous Stag... Noncontiguous S... Stage I Adult D... Stage III Adult... Stage IV Adult ... | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... vincristine sul... prednisone biopsy microarray anal... immunohistochem... gene expression... cytogenetic ana... | 19 Years - | University of Nebraska | |
| A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer | NCT00064259 | Adenocarcinoma ... Adenocarcinoma ... Diffuse Adenoca... Intestinal Aden... Mixed Adenocarc... Recurrent Esoph... Recurrent Gastr... Squamous Cell C... Stage III Esoph... Stage IIIA Gast... Stage IIIB Gast... Stage IIIC Gast... Stage IV Esopha... Stage IV Gastri... | oblimersen sodi... cisplatin fluorouracil | 19 Years - | National Cancer Institute (NCI) | |
| Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | NCT00024440 | Leukemia | filgrastim oblimersen sodi... cyclophosphamid... fludarabine pho... | 18 Years - | National Cancer Institute (NCI) | |
| Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT00017602 | Multiple Myelom... | oblimersen sodi... dexamethasone | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | NCT00062244 | Waldenström Mac... | oblimersen sodi... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | NCT00086944 | Recurrent Adult... Recurrent Grade... Recurrent Mantl... | oblimersen sodi... rituximab ifosfamide carboplatin etoposide filgrastim pegfilgrastim laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 | NCT00070343 | Melanoma (Skin) | oblimersen sodi... dacarbazine | - | National Cancer Institute (NCI) | |
| Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia | NCT00062244 | Waldenström Mac... | oblimersen sodi... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | NCT00301795 | Stage III Grade... Stage III Grade... Stage III Grade... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... | oblimersen sodi... rituximab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma | NCT00054639 | Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Adult... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Mantl... Recurrent Margi... Recurrent Small... Small Intestine... Splenic Margina... Testicular Lymp... Waldenström Mac... | oblimersen sodi... rituximab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer | NCT00059813 | Recurrent Renal... Stage IV Renal ... | recombinant int... oblimersen sodi... pharmacological... | 19 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301 | NCT00070343 | Melanoma (Skin) | oblimersen sodi... dacarbazine | - | National Cancer Institute (NCI) | |
| Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia | NCT00017589 | Leukemia | oblimersen sodi... gemtuzumab ozog... | 60 Years - | National Cancer Institute (NCI) | |
| Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer | NCT00030641 | Lung Cancer | oblimersen sodi... docetaxel | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors | NCT00054548 | Unspecified Adu... | oblimersen sodi... paclitaxel laboratory biom... pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer | NCT00055822 | Colorectal Canc... | oblimersen sodi... fluorouracil leucovorin calc... oxaliplatin | 18 Years - | The University of Texas Health Science Center at San Antonio | |
| Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate | NCT00085228 | Prostate Cancer | oblimersen sodi... docetaxel | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| Carboplatin and Etoposide With or Without Oblimersen Sodium in Treating Patients With Extensive Stage Small Cell Lung Cancer | NCT00042978 | Extensive Stage... Recurrent Small... | oblimersen sodi... carboplatin etoposide | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia | NCT00017589 | Leukemia | oblimersen sodi... gemtuzumab ozog... | 60 Years - | National Cancer Institute (NCI) | |
| Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | NCT00070083 | Lymphoma | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 19 Years - | National Cancer Institute (NCI) | |
| S0349 Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Oblimersen in Treating Patients With Advanced Diffuse Large B-Cell Non-Hodgkin's Lymphoma | NCT00080847 | Contiguous Stag... Noncontiguous S... Stage III Adult... Stage IV Adult ... | oblimersen sodi... rituximab cyclophosphamid... doxorubicin hyd... vincristine sul... prednisone laboratory biom... | 19 Years - 59 Years | National Cancer Institute (NCI) | |
| Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | NCT00086944 | Recurrent Adult... Recurrent Grade... Recurrent Mantl... | oblimersen sodi... rituximab ifosfamide carboplatin etoposide filgrastim pegfilgrastim laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma | NCT00301795 | Stage III Grade... Stage III Grade... Stage III Grade... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... | oblimersen sodi... rituximab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma | NCT00086944 | Recurrent Adult... Recurrent Grade... Recurrent Mantl... | oblimersen sodi... rituximab ifosfamide carboplatin etoposide filgrastim pegfilgrastim laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00049192 | Chronic Myeloge... Chronic Phase C... Relapsing Chron... | oblimersen sodi... imatinib mesyla... laboratory biom... | 15 Years - | National Cancer Institute (NCI) | |
| Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors | NCT00039481 | Cardiac Toxicit... Unspecified Chi... | oblimersen sodi... dexrazoxane hyd... doxorubicin hyd... cyclophosphamid... filgrastim laboratory biom... pharmacological... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer | NCT00017251 | Extensive Stage... | oblimersen sodi... carboplatin etoposide pharmacological... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | NCT00047229 | Liver Cancer | oblimersen sodi... doxorubicin hyd... | 18 Years - 120 Years | University Health Network, Toronto | |
| Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery | NCT00091078 | Gastrointestina... | oblimersen sodi... imatinib mesyla... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | NCT00047229 | Liver Cancer | oblimersen sodi... doxorubicin hyd... | 18 Years - 120 Years | University Health Network, Toronto | |
| Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) | NCT00047229 | Liver Cancer | oblimersen sodi... doxorubicin hyd... | 18 Years - 120 Years | University Health Network, Toronto | |
| Combination Chemotherapy and Oblimersen in Treating Patients With Advanced Colorectal Cancer | NCT00055822 | Colorectal Canc... | oblimersen sodi... fluorouracil leucovorin calc... oxaliplatin | 18 Years - | The University of Texas Health Science Center at San Antonio |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
